



HOOKIPA TO PRESENT AT BIOTECH IN EUROPE FORUM 2015

Vienna, Austria, September 25, 2015 – Hookipa Biotech AG, today announced that the company's Chief Executive Officer, Dr. Katherine Cohen, will provide an overview of the company's technologies and programs at the Biotech in Europe Forum 2015 (Basel, Switzerland, September 29-30; presentation on Tuesday, September 29 at 12:30 p.m. CET).

About Hookipa Biotech

Hookipa Biotech AG is developing a new class of innovative immunotherapeutics and vaccines based on its proprietary Vaxwave® technology. The Vaxwave® technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The platform is one of the most promising new technologies for next generation immunotherapy & vaccines due to its ability to stimulate both potent B-cell and CD8+ T-cell immune responses. Vaxwave® has been validated in various disease models. Unlike other vectors, Vaxwave® based immunotherapy can be applied repeatedly to boost the immune system. The Company is developing a lead product candidate HB101, a vaccine for immunization against cytomegalovirus (CMV) and also in the process of industrializing the Vaxwave® technology and building a robust product pipeline in the area of immuno-oncology and infectious diseases.

Hookipa has raised a total of € 27 million in equity finance from internationally renowned venture capital investors including Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners.

Contact:

Dr. Katherine Cohen
Chief Executive Officer

Hookipa Biotech AG
Helmut-Qualtinger-Gasse 2
1030 Vienna
Austria
Email: office@hookipabiotech.com